HER2 therapies and gastric cancer: a step forward
Ramon Andrade de Mello1, Andrea Marin Marques, António Araújo
1Ramon Andrade de Mello, António Araújo, Department of Medical Oncology, Gastrointestinal Unit, Portuguese Oncology Institute, 4200-072 Porto, Portugal.
Abstract:
Gastric cancer usually is diagnosed in advanced stages and thus current medical practice affords limited therapeutic options. However, recent studies established the role of human epidermal growth factor receptor 2 (HER2) in clinical management. Trastuzumab, an anti-HER2 monoclonal antibody, acquired a main role in advanced gastric cancer harboring HER2 overexpression and/or amplification improving survival to 17.1 mo according to trastuzumab for gastric cancer phase III trial results. Also, new promising drugs, such as c-Met inhibitors, are in development and assessment for this setting. Certainly, novel drugs will emerge in the next feel years for help oncologists improve clinical management of advanced gastric cancer providing higher survival and quality of life. In this mini-review we will discuss some issues in this regard and provide an actual overview of this setting.
Insights
Advanced gastric cancer treatment is limited, but targeting human epidermal growth factor receptor 2 (HER2) with trastuzumab has improved survival. New drugs are emerging to further enhance outcomes for patients with HER2-positive gastric cancer.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Gastric cancer diagnosis often occurs at advanced stages, limiting treatment options.
- Human epidermal growth factor receptor 2 (HER2) plays a crucial role in gastric cancer management.
- Current therapies offer limited efficacy in advanced disease settings.
Purpose of the Study:
- To review the current therapeutic landscape for advanced gastric cancer.
- To highlight the impact of HER2-targeted therapies, such as trastuzumab.
- To discuss emerging drug development for advanced gastric cancer.
Main Methods:
- Review of recent clinical studies and trial results.
- Analysis of the role of HER2 overexpression and amplification in treatment response.
- Discussion of ongoing drug development, including c-Met inhibitors.
Main Results:
- Trastuzumab, an anti-HER2 monoclonal antibody, significantly improves survival in advanced gastric cancer with HER2 overexpression/amplification (17.1 months median survival).
- HER2-targeted therapy has become a cornerstone in managing specific advanced gastric cancer subtypes.
- Emerging therapies show promise for future treatment strategies.
Conclusions:
- Targeting HER2 with trastuzumab represents a significant advancement in advanced gastric cancer treatment.
- Ongoing research into novel agents like c-Met inhibitors is crucial for improving patient survival and quality of life.
- Future oncological management of advanced gastric cancer will likely involve personalized therapies based on molecular targets.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies